Hoth Therapeutics, Inc., a biopharmaceutical company, announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer’s disease.
Hoth also secured an exclusive license agreement with respect to the use of this drug for other indications. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures, such as those involved in memory and cognition.
The disease leads to deficits in cognitive function and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. The disease is predicted to increase at least threefold between 2000 and 2050, rendering AD a world-wide public health problem.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne.
Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19.
